• Explore /
  • Poster
  • / Trial in progress: A phase 1b/2 study of the PARP inhibitor niraparib in combination with trastuzumab in patients with metastatic HER2+ breast cancer (TBCRC 050).

Trial in progress: A phase 1b/2 study of the PARP inhibitor niraparib in combination with trastuzumab in patients with metastatic HER2+ breast cancer (TBCRC 050).

Abstract Poster

Authors

Erica Stringer-Reasor

Erica Michelle Stringer-Reasor

University of Alabama at Birmingham, Birmingham, AL

Erica Michelle Stringer-Reasor , Yufeng Li , Felicia Witherspoon , Jennifer M. Specht , Jesus Del Santo Anampa Mesias , Rita Nanda , Elizabeth Claire Dees , Antonio C. Wolff , Ian E. Krop , Nancy U Lin , Mothaffar F. Rimawi , Eddy Shih-Hsin Yang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

HER2-Positive

Clinical Trial Registration Number

NCT03368729

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS1098)

DOI

10.1200/JCO.2021.39.15_suppl.TPS1098

Abstract #

TPS1098

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Fabrice Andre

Poster

2015 Gastrointestinal Cancers Symposium

Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites.

Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites.

First Author: Ozge Gumusay

First Author: Amelia Bruce Zelnak

First Author: Rachel A. Freedman